Development asset linked to Shanghai SIMR Biotech in public FDA and regional records.
pharma · Esophageal Cancer · Esophageal Squamous Cell Carcinoma
Shanghai SIMR Biotech
Shanghai Chest Hospital
Shanghai SIMR Biotech drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Shanghai, CN HQ
2014 Founded
23 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Shanghai, CN
- Founded
- 2014
- Employees
- 23
- Programs
- 3
- Drugs
- 14
- Patents
- 0
Shanghai SIMR Biotech pipeline
Portfolio lens on 14 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Shanghai SIMR Biotech drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Shanghai SIMR Biotech in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Shanghai SIMR Biotech in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: DNA topoisomerase II.
- Target
- DNA topoisomerase II
- Mechanism
- DNA topoisomerase II inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Shanghai SIMR Biotech in public FDA and regional records.
-
Development asset linked to Shanghai SIMR Biotech in public FDA and regional records.
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Shanghai SIMR Biotech in public FDA and regional records.
-
Development asset linked to Shanghai SIMR Biotech in public FDA and regional records. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor